159 episodes
The Long Run with Luke Timmerman Timmerman Report
-
- Science
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
-
Ep161: Jeff Stein on a Long-Lasting Flu Drug
Jeff Stein, CEO of San Diego-based Cidara Therapeutics, on a long-lasting drug against flu.
-
Ep160: Abe Ceesay on Precision Neuroscience
Abe Ceesay, CEO of Boston-based Rapport Therapeutics, on a precision medicine approach to neuroscience drug discovery.
-
Ep159: Jimi Olaghere on Being Functionally Cured of Sickle Cell Disease
Jimi Olaghere is one of the first patients to have been functionally cured of sickle cell disease with a CRISPR gene-edited cell therapy.
-
Ep158: David Younger and Randolph Lopez on SynBio & AI for Discovery
David Younger and Randolph Lopez, co-founders of A-Alpha Bio, on using synthetic biology and AI to discover new biologic drugs.
-
Ep157: Vineeta Agarwala of A16Z on Investing in AI for Drug Discovery
Vineeta Agarwala, general partner at A16Z's Bio & Health fund, on investing in AI for drug discovery.
-
Ep156: David Liu on New Tools and Techniques for Biology
David Liu, professor of chemistry at Harvard University and co-founder of multiple biotech companies, including Beam Therapeutics and Prime Medicine.